All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 23, 2023
Home » Topics » Respiratory, BioWorld Science

Respiratory, BioWorld Science
Respiratory, BioWorld Science RSS Feed RSS

Microscopic view of P. aeruginosa infection of mouse lung
Infection

What stops a bad guy in the lung? A good guy in the lung, of course

Jan. 20, 2023
By Anette Breindl
No Comments
Researchers at the Barcelona Institute of Science and Technology’s Center for Genomic Regulation (CRG) and Pulmobiotics Ltd. have used one bacterium to fight another. In mouse models, the team used engineered Mycoplasma pneumoniae to treat Pseudomonas aeruginosa, the chief culprit in ventilator-associated pneumonia (VAP).
Read More
Biomarkers

CMKLR1 PET imaging found tied to experimental acute lung injury

Jan. 19, 2023
No Comments
Chemokine-like receptor 1 (CMKLR1) is a G protein-coupled receptor for chemerin and resolvin E1 that plays a key role in the recruitment and activation of macrophages, natural killer cells and plasmacytoid dendritic cells in inflammatory diseases.
Read More
3D renderings of RSV
Respiratory

Targeting prefusion state is better bet for RSV vaccines

Jan. 5, 2023
By Mar de Miguel
No Comments
After comparing the response to the two types of vaccines for the respiratory syncytial virus (RSV) based on its fusion protein (F), prefusion (pre-F) versus postfusion (post-F) vaccines, scientists at the National Institutes of Health (NIH) and Astrazeneca plc have demonstrated that targeting the pre-F protein led to better protection. No more bets on RSV immunization based on the post-F protein of the virus. Laboratories can now bet all on red for the pre-F technology.
Read More
Respiratory

Genentech patents new LATS1 and/or LATS2 inhibitors for ARDS

Jan. 3, 2023
No Comments
Genentech Inc. has disclosed 2,8-diazaspiro [4.5] decane compounds acting as serine/threonine-protein kinase LATS1 and/or LATS2 inhibitors reported to be useful for the treatment of acute respiratory distress syndrome (ARDS).
Read More
Respiratory

Azcuris reports development of TSLP/TSLPR interaction inhibitors

Dec. 29, 2022
No Comments
Research at Azcuris Co. Ltd. has led to the development of thymic stromal lymphopoietin (TSLP)/cytokine receptor-like factor 2 (CRLF2; TSLPR) interaction inhibitors, which are reported to be useful for the treatment of autoimmune diseases, chronic obstructive pulmonary disease (COPD), allergy, asthma, allergic rhinitis and chronic rhinosinusitis.
Read More
Respiratory

NLRP3 inflammasome inhibitors described in Roche patent

Dec. 29, 2022
No Comments
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Read More
Colorized scanning electron micrograph of human respiratory syncytial virus.
Infection

Poolbeg's collaboration with Onethree Biotech identifies potential RSV drug candidates

Dec. 22, 2022
No Comments
Poolbeg Pharma plc has identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with Onethree Biotech Inc.
Read More
Respiratory

Discovery of a novel CB2 receptor agonist, YX-2102, with promising activity in models of PF

Dec. 20, 2022
No Comments
Investigators from Army Medical University reported the discovery and preclinical characterization of a novel cannabinoid receptor 2 (CB2 receptor) agonist, YX-2102, being developed as a potential therapeutic candidate for alleviating lung fibrosis.
Read More
Respiratory

Roche discovers new PDK1 inhibitors

Dec. 15, 2022
No Comments
Roche has synthesized pyruvate dehydrogenase kinase 1 (PDK1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus, psoriasis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and cancer.
Read More
Respiratory

Vertex cleared to enter clinic with mRNA therapy VX-522 for cystic fibrosis

Dec. 13, 2022
No Comments
Vertex Pharmaceuticals Inc. has received clearance from the FDA for its IND application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF).
Read More
Previous 1 2 3 4 5 6 7 8 9 … 662 663 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 23, 2022.
  • Woman with headache

    Nasal spray Zavzpret cleared, Pfizer showing ‘growth on every measure’ in migraine

    BioWorld
    Pricing won’t be known until later for Pfizer Inc.’s Zavzpret (zavegepant), which became the first and only calcitonin gene-related peptide receptor antagonist...
  • Kirill Pevzner and Eran Seger - Protai

    AI drug discovery startup Protai raises $12M in seed funding

    BioWorld
    Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...
  • Targets with arrows

    Flagship puts $50M toward targeted tissue-homing tech startup

    BioWorld
    In an ideal world, when a patient takes a medicine, it acts only at the specific site of disease in the human body whilst sparing healthy tissues. But it almost...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing